» Articles » PMID: 20592901

Seoul Neuropsychological Screening Battery-dementia Version (SNSB-D): a Useful Tool for Assessing and Monitoring Cognitive Impairments in Dementia Patients

Overview
Specialty General Medicine
Date 2010 Jul 2
PMID 20592901
Citations 200
Authors
Affiliations
Soon will be listed here.
Abstract

The Seoul Neuropsychological Screening Battery (SNSB) is one of the standardized neuropsychological test batteries widely used in Korea. However, it may be a bit too lengthy for patients with decreased attention span; and it does not provide the score of global cognitive function (GCF), which is useful for monitoring patients longitudinally. We sought to validate a dementia version of SNSB (SNSB-D) that was shorter than the original SNSB and contained only scorable tests with a GCF score of 300. We administered SNSB-D to patients with mild cognitive impairment (MCI) (n=43) and Alzheimer's disease (AD) (n=93), and normal controls (NC) (n=77). MCI and AD groups had GCF scores significantly different from NC group, and GCF scores were able to distinguish patients with Clinical Dementia Rating of 0.5 and 1. Test-retest reliability was high, with a correlation coefficient of 0.918 for AD, 0.999 for MCI, and 0.960 for NC. The GCF score significantly correlated with the Mini-Mental State Examination (MMSE). Through ROC-curve analysis, GCF scores were found to yield more accurate diagnoses than the MMSE. The SNSB-D is a valid, reliable tool for assessing the overall cognitive function, and can be used to monitor cognitive changes in patients with dementia.

Citing Articles

Physical Activity, Alzheimer Plasma Biomarkers, and Cognition.

Kim S, Shin D, Ham H, Kim Y, Gu Y, Kim H JAMA Netw Open. 2025; 8(3):e250096.

PMID: 40042844 PMC: 11883494. DOI: 10.1001/jamanetworkopen.2025.0096.


Altered triple network model connectivity is associated with cognitive function and depressive symptoms in older adults.

Kolobaric A, Andreescu C, Gerlach A, Jasarevic E, Aizenstein H, Pascoal T Alzheimers Dement. 2025; 21(3):e14493.

PMID: 40042417 PMC: 11881620. DOI: 10.1002/alz.14493.


Comparison of accumulation rates of beta-amyloid tracers and their relationship with cognitive changes.

Cho S, Kang H, Ham H, Moon S, Jang H, Yun J Sci Rep. 2025; 15(1):7072.

PMID: 40016250 PMC: 11868567. DOI: 10.1038/s41598-025-90642-8.


Subregion-specific associations of the basal forebrain with sleep and cognition in Parkinson's disease.

Lee J, Kim H, Ahn S, Park M, Yoo H, Lyoo C NPJ Parkinsons Dis. 2025; 11(1):33.

PMID: 39979309 PMC: 11842645. DOI: 10.1038/s41531-025-00880-w.


Gait impairment associated with neuroimaging biomarkers in Alzheimer's disease.

Kim S, Kim D, Hong J, Mun K, Jung D, Hong I Sci Rep. 2025; 15(1):5539.

PMID: 39953283 PMC: 11828857. DOI: 10.1038/s41598-025-90020-4.


References
1.
Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

2.
Metz C . Basic principles of ROC analysis. Semin Nucl Med. 1978; 8(4):283-98. DOI: 10.1016/s0001-2998(78)80014-2. View

3.
Petersen R, Smith G, Waring S, Ivnik R, Tangalos E, Kokmen E . Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56(3):303-8. DOI: 10.1001/archneur.56.3.303. View

4.
Chandler M, Lacritz L, Hynan L, Barnard H, Allen G, Deschner M . A total score for the CERAD neuropsychological battery. Neurology. 2005; 65(1):102-6. DOI: 10.1212/01.wnl.0000167607.63000.38. View

5.
ROSEN W, Mohs R, Davis K . A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141(11):1356-64. DOI: 10.1176/ajp.141.11.1356. View